Corbus Pharmaceuticals Holdings, Inc. (CRBP) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2024-03-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2024-03-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2024-03-31..
Borrowing debt
Overview →Financial period ending 2024-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2024-03-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2024-03-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2024-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 12.76M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 0.00 USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 125.74M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | (m) | (m) | $12.76M | $0.00 | (m) | (m) | $125.74M | (m) |
| 2023-12-31 | (m) | (m) | $15.91M | $0.00 | (m) | (m) | $28.27M | (m) |
| 2023-09-30 | (m) | (m) | $17.85M | $0.00 | (m) | (m) | $36.28M | (m) |
| 2023-06-30 | (m) | (m) | $7.02M | $11.32M | (m) | (m) | $43.72M | (m) |
| 2023-03-31 | (m) | (m) | $5.01M | $13.97M | (m) | (m) | $51.65M | (m) |
| 2022-12-31 | (m) | (m) | $2.80M | $15.98M | (m) | (m) | $66.31M | (m) |
| 2022-09-30 | (m) | (m) | $9.88M | $9.39M | (m) | (m) | $73.83M | (m) |
| 2022-06-30 | (m) | (m) | $7.47M | $11.61M | (m) | (m) | $82.07M | (m) |
| 2022-03-31 | (m) | (m) | $5.18M | $13.73M | (m) | (m) | $95.68M | (m) |
| 2021-12-31 | (m) | (m) | $3.09M | $15.64M | (m) | (m) | $107.73M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $18.55M | (m) | $106.86M | $119.57M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $18.37M | (m) | $106.45M | $120.61M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $18.20M | (m) | $124.01M | $140.15M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $18.03M | (m) | (m) | $102.29M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $17.86M | (m) | (m) | $95.84M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |